2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure …
JW McEvoy, CP McCarthy, RM Bruno… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
V Perkovic, KR Tuttle, P Rossing… - … England Journal of …, 2024 - Mass Medical Soc
Background Patients with type 2 diabetes and chronic kidney disease are at high risk for
kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would …
kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would …
ChatGPT: Is this version good for healthcare and research?
R Vaishya, A Misra, A Vaish - … & Metabolic Syndrome: Clinical Research & …, 2023 - Elsevier
Background and aims There have been advancements in artificial intelligence (AI) and deep
learning in the past decade. Recently, OpenAI Inc. has launched a new chatbot, called …
learning in the past decade. Recently, OpenAI Inc. has launched a new chatbot, called …
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
C Baigent, JR Emberson, R Haynes, WG Herrington… - The Lancet, 2022 - thelancet.com
Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …
[PDF][PDF] 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association
BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
People with type 2 diabetes and chronic kidney disease have a high risk for kidney failure
and cardiovascular (CV) complications. Glucagon-like peptide-1 receptor agonists and …
and cardiovascular (CV) complications. Glucagon-like peptide-1 receptor agonists and …
2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology …
MM Kittleson, GS Panjrath, K Amancherla… - Journal of the American …, 2023 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …
decision pathways, health policy statements, appropriate use criteria) to provide members …
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …